This list is an analysis based on recent market events. It's not an investment recommendation.
About
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University. The company was incorporated in 2006 and is based in Camberwell, Australia.
Show more...
CEO
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.
The current price of 1AD.AU is A$0.01 AUD — it has increased by +0% in the past 24 hours. Watch AdAlta Limited stock price performance more closely on the chart.
What is AdAlta Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AdAlta Limited stocks are traded under the ticker 1AD.AU.
What is AdAlta Limited market cap?▼
Today AdAlta Limited has the market capitalization of 11.48M
When is the next AdAlta Limited earnings date?▼
AdAlta Limited is going to release the next earnings report on August 21, 2026.
What is AdAlta Limited revenue for the last year?▼
AdAlta Limited revenue for the last year amounts to 0 AUD.
What is AdAlta Limited net income for the last year?▼
1AD.AU net income for the last year is -9M AUD.
How many employees does AdAlta Limited have?▼
As of April 29, 2026, the company has 1 employees.
In which sector is AdAlta Limited located?▼
AdAlta Limited operates in the Health & Wellness sector.
When did AdAlta Limited complete a stock split?▼
The last stock split for AdAlta Limited was on December 02, 2025 with a ratio of 1:10.
Where is AdAlta Limited headquartered?▼
AdAlta Limited is headquartered in Camberwell, Australia.